Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Cannabinoids in the management of difficult to treat pain

Authors Ethan B Russo

Published Date May 2008 Volume 2008:4(1) Pages 245—259

DOI http://dx.doi.org/10.2147/TCRM.S1928

Published 13 May 2008

Ethan B Russo

GW Pharmaceuticals, Vashon, WA, USA

Abstract: This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making

Nnabugwu II, Ugwumba FO, Enivwenae OA, Udeh EI, Otene CO, Nnabugwu CA

Clinical Interventions in Aging 2015, 10:89-93

Published Date: 30 December 2014

Back to basics: tackling the challenges to bedside teaching

Dewji R, Dewji A, Gnanappiragasam D

Advances in Medical Education and Practice 2015, 6:17-18

Published Date: 23 December 2014

Antibacterial properties of silver nanoparticles synthesized using Pulicaria glutinosa plant extract as a green bioreductant

Khan M, Khan ST, Khan M, Adil SF, Musarrat J, Al-Khedhairy AA, Al-Warthan A, Siddiqui MRH, Alkhathlan HZ

International Journal of Nanomedicine 2014, 9:3551-3565

Published Date: 28 July 2014

Epidemiology of nonfatal stroke and transient ischemic attack in Al-Kharga District, New Valley, Egypt

Farghaly WM, El-Tallawy HN, Shehata GA, Rageh TA, Abdel-Hakeem NM, Elhamed MA, Al-Fawal BM, Badry R

Neuropsychiatric Disease and Treatment 2013, 9:1785-1790

Published Date: 18 November 2013

Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide

Cha KH, Cho KJ, Kim MS, Kim JS, Park HJ, Park J, Cho W, Park JS, Hwang SJ

International Journal of Nanomedicine 2012, 7:5565-5575

Published Date: 25 October 2012

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012